Stomach and esophageal cancer care in Greece
Part of Cancer, Digestive system clinical trials.
This study is for people with stomach or esophageal cancer in Greece. It is not a treatment study; it simply looks at how patients are diagnosed and treated in regular practice, so participating won't change your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You were diagnosed with stomach or gastroesophageal junction (where the stomach meets the esophagus) cancer.
- Your cancer is stage II, III, or IV (meaning it has spread beyond the earliest stage).
- You were diagnosed after June 2025 (during the study period).
- You have not needed treatment for another cancer in the last 5 years.
- You are in Greece (the study is only for patients treated there).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at stomach (or stomach–esophagus junction) cancer tissue, treatment details, and patient-reported experiences to better predict how you may respond to standard chemotherapy. It may help personalize future treatment by identifying markers that connect your tumor environment and your expected outcomes.
This study keeps an organized record of people diagnosed with esophagus, gastroesophageal junction, or stomach cancer. It helps researchers learn from real-world outcomes, based on health information collected over time.
This trial looks at tiny pieces of DNA found outside cells in stomach tissue to better understand how gastric (stomach) cancer starts and progresses. It may help future patients by improving how doctors study stomach cancer from biopsy and surgical samples.
This study collects health information from people at different stages of stomach cancer risk, including those with precancerous changes, healthy individuals, and those with early stomach cancer. The goal is to better understand and prevent stomach cancer.
This trial tests a combination of two treatments: an immunotherapy drug (pembrolizumab, which helps your immune system fight cancer) and chemotherapy (FLOT) for advanced stomach or esophageal junction cancer. The goal is to see if this combination is safe and works better than standard care.
This trial tests a new study drug (SAR445877) for adults with advanced stomach or gastroesophageal junction cancer that has worsened after at least one prior treatment. It aims to find the best dose and see if the drug can help shrink or slow the cancer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.